Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 12:53pm EST

By Donato Paolo Mancini

Novartis AG's (NOVN.EB) closed higher on Thursday after jumping on news of a ruling that suggested that market exclusivity for the company's multiple-sclerosis blockbuster drug Gilenya in the U.S. will likely be extended.

"A favorable resolution of the dosage regimen patent litigation" may lengthen the period in which the drug is free from generic competition, according to a Novartis document seen by Dow Jones Newswires.

The note was sent out at around midday Thursday, two analysts told Dow Jones, and shares started climbing around that time. One of the analysts said the market wasn't expecting the decision, so that sent the share price up.

According to the document, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued a decision upholding the validity of the dosage-regimen patent on Wednesday. The decision can be appealed, the document said.

Gilenya had sales of $3.19 billion in 2017, according to the company's annual report.

Novartis said it was pleased with the decision, and that it expected to maintain exclusivity until August 2019.

Shares closed up 4.1% at CHF78.94.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
02/13NOVARTIS : receives FDA approval for Egaten® for the treatment of fascioliasis, ..
GL
02/13CLINIGEN : agrees to buy U.S. rights to Novartis' cancer drug Proleukin
RE
02/11RECRO PHARMA : in New Supply Agreement with Novartis
DJ
02/07GLOBAL MARKETS LIVE : General Motors, Sonos, Chipotle Mexican Grill, Publicis ....
02/07NOVARTIS : CEO lauds Trump administration plan to overhaul rebates
RE
02/06NOVARTIS INDIA : Q3 profit dips 31% to Rs 13 crore
AQ
02/05NOVARTIS : Alcon eye-care unit to enter Swiss index after spin off
RE
02/05Merck KGaA, GSK Enter Immuno-Oncology Deal Worth Up to $4.23 Billion -- Updat..
DJ
02/04SURFACE ONCOLOGY : Keeps Worldwide Rights to SRF388 After Novartis Passes on Opt..
DJ
02/04Biopharmaceutical Market to Reach USD 218483.0 Million by 2023 Growing at a C..
AQ
More news
Financials ($)
Sales 2019 53 517 M
EBIT 2019 14 117 M
Net income 2019 8 856 M
Debt 2019 14 672 M
Yield 2019 3,32%
P/E ratio 2019 22,10
P/E ratio 2020 19,81
EV / Sales 2019 4,55x
EV / Sales 2020 4,27x
Capitalization 229 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 94,4 $
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.19%228 685
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
MERCK AND COMPANY4.45%207 536
ELI LILLY AND COMPANY4.35%129 746